NCT02412423

Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".

Conditions

• Hematopoietic Stem Cell Transplantation

Interventions

Type	Name	Description
DRUG	post-transplantation cyclophosphamide

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-08-01
• Completion: 2017-03-01
• First posted: 2015-04-09
• Last updated: 2020-09-17

Locations

1 site across 1 country: China